Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Pfizer

Share:
Related PFE
Fast Money Picks For March 5: Foot Locker, Pfizer And More
Evercore ISI Technical Analysis: The 'Single Best Idea'
Pfizer's Strong FCF Means Big Dividend Growth (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Pfizer (NYSE: PFE), and raised its price target from $27.00 to $31.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Pfizer closed on Tuesday at $26.74.

Latest Ratings for PFE

DateFirmActionFromTo
Feb 2015JefferiesMaintainsBuy
Feb 2015JP MorganMaintainsOverweight
Feb 2015CitigroupMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters